Clinical stage biopharmaceutical development company BioLineRx, Ltd.(BLRX) Monday said it has enrolled its first patient in a Phase I/II trial for BL-8020, an orally available, interferon-free treatment for the Hepatitis C virus. The patient was enrolled at the Hôpital Cochin in Paris, France.
The study is expected to be conducted at two clinical sites in France and include up to 32 HCV-infected patients of any genotype who have previously failed or relapsed following treatment with the standard-of-care. The primary endpoint of the study is to evaluate the effect of a 16-week combination therapy with Ribavirin and HCQ, said the firm and added that BL-8020's safety and efficacy have been demonstrated in a number of pre-clinical studies.
Commenting on the development, Dr. Kinneret Savitsky, CEO of BioLineRx said, "... Based on its pre-clinical results, unique mechanism of action and synergistic effect with other anti-HCV compounds, we are very hopeful that BL-8020 will indeed enhance the activity of other available Hepatitis C treatments, thereby improving Hepatitis C care. We look forward to the partial results from the Phase I/II trial expected towards the end of 2013."
Hepatitis C infection is a blood-borne infection of the liver caused by the Hepatitis C virus which becomes chronic in about 85 percent of cases.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.